Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteoporosis and hormone replacement therapy].

Christian Roux1

  • 1Service de rhumatologie, Université René Descartes, Hôpital Cochin, 27, rue du Faubourg, St Jacques, 75014 Paris. christian.roux@cch.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|April 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare disease care pathways profile in France: leveraging hospital big data to characterize natural history in osteogenesis imperfecta.

JBMR plus·2026
Same author

Long-Term Effects of Rheumatoid Arthritis Treatments on Bone Mineral Density: 8-Year-Follow-Up Data from Real-World Practice.

Journal of clinical medicine·2026
Same author

Marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis.

JBMR plus·2026
Same author

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry.

Joint bone spine·2025
Same author

Opportunistic screening for osteoporosis and vertebral fracture using CT attenuation from 18F-fluorocholine PET/CT in patients with prostate cancer.

RMD open·2025
Same author

Cartilage turnover, but not novel synovial collagen marker, is associated with joint damage progression in osteoarthritis patients.

Rheumatology (Oxford, England)·2025

Hormone replacement therapy significantly reduces fracture risk in postmenopausal women. However, careful consideration of duration and benefit-risk balance is crucial due to potential side effects.

Area of Science:

  • Endocrinology and Bone Metabolism
  • Menopause and Hormone Therapy Research

Context:

  • Postmenopausal osteoporosis is a significant health concern, characterized by bone loss and increased resorption due to estrogen deficiency.
  • Epidemiological studies suggested hormone replacement therapy (HRT) could mitigate these effects.

Purpose:

  • To evaluate the efficacy of hormone replacement therapy in preventing bone loss and reducing fracture risk in postmenopausal women.
  • To assess the long-term benefits and risks associated with HRT, including its impact on climacteric disorders and breast cancer incidence.

Summary:

  • The Women's Health Initiative (WHI) randomized controlled trial confirmed that HRT reduces fracture risk by approximately 30% in postmenopausal women.
  • The study highlighted the need to carefully consider HRT duration and the benefit-risk ratio, balancing benefits for menopausal symptoms against increased breast cancer risk.

Related Experiment Videos

  • Individual risk assessment for vascular events and fractures, incorporating clinical factors and bone density measurements, is recommended during menopause.

    • Impact:

    • Provides robust evidence supporting HRT's anti-fracture efficacy in postmenopausal women.
    • Informs clinical decision-making regarding HRT, emphasizing personalized risk-benefit assessments.
    • Highlights the importance of ongoing research into optimal HRT strategies and long-term safety profiles.